Melanoma Molecular Profiling Analysis

Inclusion Criteria: * Primary melanoma with the following Breslow thickness and stage * ≥ 2 mm with ulceration, T3b * ≥ 4 mm without (T4a) or with (T4b) ulceration * Patients with a biopsied tumor that has not been widely resected will also be eligible for study according to the above-specified criteria for tumor thickness and stage. * Age 12 years or older. * Patients must have documented hemoglobin level of 10g/dL or higher. This can be drawn on the day of consent, or be documented from a previous visit within the past 30 days * Subjects must have provided written, informed consent prior to any study procedures: collection of blood and LN tissue specimens for this protocol. Exclusion Criteria: * Serious illnesses that may be considered a contraindication to surgery as determined by the physician investigator. If a subject is cleared for surgery as clinically indicated (wide excision of the primary melanoma and sentinel lymph node biopsy), subject would be eligible. * Any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the Principal Investigator or Co-Investigators, could prevent adequate informed consent or compromise participation in the clinical trial. * Active infection or antibiotics within one-week prior to study * Systemic steroid or other immunosuppressive therapy administered for more than 10 days within 4 weeks of enrollment.